Sun Enters Japan Through Divested Novartis Portfolio

 
• By Ian Haydock

Sun Pharmaceutical Industries Ltd. is entering the Japanese pharma market by acquiring a bundle of 14 established prescription brands from Novartis AG's local subsidiary, in an anticipated move that echoes a similar transaction between Takeda Pharmaceutical Co. Ltd. and Teva Pharmaceutical Industries Ltd. last year.

More from Japan

More from Focus On Asia